On 30 May 2016, orphan designation (EU/3/16/1667) was granted by the European Commission to Aceso Biologics Consulting Ltd, United Kingdom, for rovalpituzumab tesirine for the treatment of small cell lung cancer.
The sponsorship was transferred to Abbvie Ltd, United Kingdom, in February 2017 and subsequently to AbbVie Deutschland GmbH & Co. KG, in May 2018.
|Disease / condition||
Treatment of small cell lung cancer
|Date of decision||
|Orphan decision number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.